Search

OTI-030

Iodofiltic acid I-123

NOX-100

NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

Ciluprevir

The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

rhIGFBP-3

rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed...

KAI-1455

Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia. … In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult.

SNX-5422

SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. … As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.

Sovateltide

SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemothe...

Glesatinib

Onalespib